Company intelligence / Profile preview

Yakult Honsha

Ownership: Private
Development stage: Other

Overview

The company’s flagship probiotic drink "Yakult" has been sold globally since the mid-twentieth century with strong evidence of safety and gut health benefits. Its pharmaceutical division markets drugs including the chemotherapeutic agent irinotecan ("campto"), which has regulatory approval for use in cancer treatment. The company continues to expand its manufacturing footprint internationally.

Therapeutic areas: GastroenterologyOncologyOther
Modalities: Live biotherapeutic product therapy (probiotic drinks)Small molecule (pharmaceuticals such as irinotecan)Protein (some functional foods and supplements)
Industry: Biotech

Drug pipeline

13 assets

irinotecan

Approved

12 more assets in the full pipeline.

Request access →

Partnerships

Danone held a significant stake (~21% until reduced to ~7% in recent years), joint venture for India market with Danone

Beyond the preview

Go deeper on Yakult Honsha.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yakult Honsha.

Explore the full profile